Orphazyme A/S (CPH: ORPHA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 51.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.42M |
| Shares Out | 41.71K |
| EPS (ttm) | -323.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140 |
| Open | 1,180.20 |
| Previous Close | 1,199.40 |
| Day's Range | 1,180.00 - 1,248.80 |
| 52-Week Range | 407.00 - 1,525.00 |
| Beta | 0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 20, 2024 |
About Orphazyme
Orphazyme A/S does not have significant operations. Previously, it was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is based in Herlev, Denmark. [Read more]
Financial Performance
Financial StatementsNews
Orphazyme Announces Publication of 2022 Financial Results and Annual Report
Company announcement
Orphazyme reports financial results in Interim Report First Half 2022
Company announcement Orphazyme A/S No. 36/2022 www.orphazyme.com Company Registration No. 32266355
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Orphazyme A/SCompany announcement No. 30/2022 Annual reportwww.orphazyme.com Company Registration No. 32266355
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Orphazyme A/SCompany announcement No. 29/2022 Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Orphazyme A/S in restructuring Company announcement No. 24/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme announces update on in-court restructuring proceedings
Orphazyme A/S in restructuring Company announcement No. 23/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs
Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled fo...
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
Orphazyme A/S Company announcement No. 13/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme A/S has filed for voluntary delisting of ADSs
Orphazyme A/S Company announcement No. 12/2022 www.orphazyme.com Company Registration No. 32266355
Notice of in-court restructuring proceedings of Orphazyme A/S
Orphazyme A/S Company announcement No. 11/2022 www.orphazyme.com Company Registration No. 32266355
Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine wh...
Commencement of in-court restructuring of Orphazyme A/S
Orphazyme A/S Company announcement No. 10/2022Inside information www.orphazyme.com Company Registration No. 32266355
Anders Vadsholt takes over as CEO of Orphazyme
Company announcement No. 08/2022 www.orphazyme.com Company Registration No. 32266355
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease...
EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application
Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The appli...
Orphazyme announces update on regulatory review of arimoclomol in the European Union
Orphazyme A/S Company ann ouncement No. 07/2022Inside information www.orphazyme.com Company Registration No. 32266355
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease...
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States
Orphazyme A/S Investor n ews No. 02/2022 www.orphazyme.com Company Registration No. 32266355
Orphazyme to present additional data on arimoclomol's mechanism of action during 2022 Annual WORLDSymposium™
Orphazyme A/S Investor News No. 01/2022 www.orphazyme.com Company Registration No. 32266355
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
Orphazyme A/S Company announcement No. 03/2022Inside information www.orphazyme.com Company Registration No. 32266355
Orphazyme Tightens FY21 Revenue Outlook
Orphazyme A/S (NASDAQ: ORPH) expects FY21 sales of DKK 35 million – DKK 37 million, compared to the previous guidance of DKK 30 million – DKK 40 million. It anticipates operating expenses of DKK 665 m...
Orphazyme updates 2021 financial outlook
Orphazyme A/SCompany announcement No. 01/2022Inside information Company Registration No. 32266355
Orphazyme announces changes to the Board of Directors
Orphazyme A/SCompany announcement No. 27/2021Company Registration No. 32266355
Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen
Orphazyme A/SCompany announcement No. 25/2021Company Registration No. 32266355
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenera...